Arrowhead Research this week released a white paper detailing the dynamic polyconjugate siRNA-delivery technology it picked up through its recent acquisition of Roche's RNA therapeutics assets.
"Studies in non-human primates have shown that [dynamic polyconjugates, or] DPCs, are highly effective and have safety margins well beyond those currently achievable by other systems,” Arrowhead President and CEO Christopher Anzalone said in a statement. “Moreover, the modular nature of DPC technology and its ability to optimize individual components within the same polymer provide the potential to target all types of cells.”
The white paper can be found here.
The delivery technology was originally developed by Mirus Bio, which Roche acquired in 2008 for $125 million (GSN 7/24/2008).
Despite this and additional investments in RNAi, Roche announced about two years later that it was halting all of its in-house research and development on the gene-silencing technology as part of a broader restructuring effort (GSN 11/18/2010).
Last month, Arrowhead disclosed that it had signed a deal acquiring these assets from Roche in exchange for roughly 10 percent of its stock and million-dollar late-stage milestones (GSN 10/27/2011).